Bio

Education & Certifications


  • Bachelor of Science, Brown University, Biophysics (2008)

Clerkships


  • 2012 Spring - MED 300A General Medicine Core Clerkship
  • 2012 Winter - MED 303B Cardiology Clerkship
  • 2012 Winter - MED 300A General Medicine Core Clerkship
  • 2011 Autumn - NENS 301A General Neurology Core Clerkship
  • 2011 Autumn - PSYC 300A Basic Core Psychiatry Clerkship
  • 2011 Autumn - SURG 300A General Surgery Clerkship
  • 2011 Summer - OBGYN 300A Basic Gynecology and Obstetrics Clerkship
  • 2011 Summer - SURG 300A General Surgery Clerkship

Research & Scholarship

Lab Affiliations


Publications

Journal Articles


  • Aptamer-Targeted Antigen Delivery. Molecular therapy : the journal of the American Society of Gene Therapy Wengerter, B. C., Katakowski, J. A., Rosenberg, J., Park, C. G., Almo, S. C., Palliser, D., Levy, M. 2014

    Abstract

    Effective therapeutic vaccines often require activation of T cell-mediated immunity. Robust T cell activation, including CD8 T cell responses, can be achieved using antibodies or antibody fragments to direct antigens of interest to professional antigen presenting cells. This approach represents an important advance in enhancing vaccine efficacy. Nucleic acid aptamers present a promising alternative to protein-based targeting approaches. We have selected aptamers that specifically bind the murine receptor, DEC205, a C-type lectin expressed predominantly on the surface of CD8α+ dendritic cells (DCs) that has been shown to be efficient at facilitating antigen cross-presentation and subsequent CD8+ T cell activation. Using a minimized aptamer conjugated to the model antigen ovalbumin (OVA), DEC205-targeted antigen cross-presentation was verified in vitro and in vivo by proliferation and cytokine production by primary murine CD8+ T cells expressing a T cell receptor specific for the MHC I-restricted OVA257-264 peptide SIINFEKL. Compared with a nonspecific RNA of similar length, DEC205 aptamer-OVA-mediated antigen delivery stimulated strong proliferation and production of IFN-γ and IL-2. The immune responses elicited by aptamer-OVA conjugates were sufficient to inhibit growth of established OVA-expressing B16 tumor cells. Our results demonstrate a new application of aptamer technology for the development of effective T cell-mediated vaccines.Molecular Therapy (2014); doi:10.1038/mt.2014.51.

    View details for DOI 10.1038/mt.2014.51

    View details for PubMedID 24682172

  • Images in clinical medicine. Bilateral digital ischemia. The New England journal of medicine Rosenberg, J. M., Rosenberg, R. 2014; 370 (12): 1148

    View details for DOI 10.1056/NEJMicm1309192

    View details for PubMedID 24645947

  • Portal Vein Thrombosis Following Laparoscopic Sleeve Gastrectomy for Morbid Obesity JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS Rosenberg, J. M., Tedesco, M., Yao, D. C., Eisenberg, D. 2012; 16 (4): 639-643

    Abstract

    Portal vein thrombosis has been documented after laparoscopic general surgery and has been uncommonly observed after laparoscopic bariatric surgery. Among bariatric operations, the sleeve gastrectomy is being performed with ever-increasing frequency. Here we report the case of a man who presented with portal vein thrombosis after laparoscopic sleeve gastrectomy.A 41-y-old man underwent an uneventful laparoscopic sleeve gastrectomy for the treatment of morbid obesity, and presented on postoperative day 10 with nonfocal abdominal pain, nausea, vomiting, and leukocytosis. Computed tomography revealed portal vein thrombosis, which was found in the setting of Clostridium difficile colitis.Portal vein thrombosis may be identified with increasing frequency as the number of laparoscopic bariatric operations continues to increase. A high index of suspicion is necessary to diagnose this rare, but potentially lethal, complication.

    View details for DOI 10.4293/108680812X13517013316636

    View details for Web of Science ID 000314201800023

    View details for PubMedID 23484577

  • Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies ARTHRITIS RESEARCH & THERAPY Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J. 2012; 14 (1)

    Abstract

    Autoreactivity to histones is a pervasive feature of several human autoimmune disorders, including systemic lupus erythematosus (SLE). Specific post-translational modifications (PTMs) of histones within neutrophil extracellular traps (NETs) may potentially drive the process by which tolerance to these chromatin-associated proteins is broken. We hypothesized that NETs and their unique histone PTMs might be capable of inducing autoantibodies that target histones.We developed a novel and efficient method for the in vitro production, visualization, and broad profiling of histone-PTMs of human and murine NETs. We also immunized Balb/c mice with murine NETs and profiled their sera on autoantigen and histone peptide microarrays for evidence of autoantibody production to their immunogen.We confirmed specificity toward acetyl-modified histone H2B as well as to other histone PTMs in sera from patients with SLE known to have autoreactivity against histones. We observed enrichment for distinctive histone marks of transcriptionally silent DNA during NETosis triggered by diverse stimuli. However, NETs derived from human and murine sources did not harbor many of the PTMs toward which autoreactivity was observed in patients with SLE or in MRL/lpr mice. Further, while murine NETs were weak autoantigens in vivo, there was only partial overlap in the immunoglobulin G (IgG) and IgM autoantibody profiles induced by vaccination of mice with NETs and those seen in patients with SLE.Isolated in vivo exposure to NETs is insufficient to break tolerance and may involve additional factors that have yet to be identified.

    View details for DOI 10.1186/ar3707

    View details for Web of Science ID 000304698800039

    View details for PubMedID 22300536

  • Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies (vol 14, R25, 2012) ARTHRITIS RESEARCH & THERAPY Liu, C. L., Tangsombatvisit, S., Rosenberg, J. M., Mandelbaum, G., Gillespie, E. C., Gozani, O. P., Alizadeh, A. A., Utz, P. J. 2012; 14 (4)

    View details for DOI 10.1186/ar3933

    View details for Web of Science ID 000314974600049

Stanford Medicine Resources: